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Abstract
Background: South African (SA) Black women have a high prevalence of preeclampsia and HIV, both conditions
associated with increased inflammation. miR-146a is an inflammatory-associated miR and a common single
nucleotide polymorphism (rs2910164) has been associated with several disease conditions. To date, this SNP has
not been investigated in SA Black women. We therefore aimed to investigate the miR-146a G > C SNP in SA
Blacks with preeclampsia, and further examine possible association among preeclamptic (PE) women with HIV
infection on HAART.
Methods: This hospital-based, case-control study included 95 normotensive and 98 PE Black SA women (aged 16–46
years old). Patients and controls were genotyped by PCR-RFLP. Using a Cytometric Bead Array assay, serum cytokine
levels (including Th1- and Th2-related cytokines) were determined in 4 groups of pregnant women, viz: normotensive,
HIV infected, PE + HIV infected, and PE women.
Results: There was no significant association between the miR-146a polymorphism and PE susceptibility in our data.
However, in the subgroup analyses, the variant genotypes (GC/CC) were significantly associated with lower severe PE
risk (p = 0.0497), more especially in the presence of HIV and HAART (p = 0.017). In the normotensive group,
the variant genotypes were associated with lower IL-2 in both the total normotensive group (269 ± 1.26 (36)
vs 273 ± 1.31 (23); p = 0.035) and the PE HIV+ sub-group 265 ± 1.54 (19) vs 271 ± 1.38 (11); p = 0.008).
Conclusions: Our study suggests that miR-146a rs2910164 polymorphism might not be associated with PE
susceptibility, cytokines or related features. However, the miR-146a GC/CC genotype might reduce susceptibility to severe
PE, which might be further influenced by the presence of co-morbid HIV infection among pregnant women on HAART.
This variant genotype may also be associated with reduced circulating IL-2 levels and thus reduced pro-inflammatory
response in normotensive women, which may be further influenced by the presence of HIV infection and HAART.
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Background
Preeclampsia (PE) and HIV infection contribute signifi-
cantly to adverse maternal and perinatal outcomes glo-
bally [1, 2]. In developing countries such as South Africa,
the prevalence of both conditions remains high and these
co-morbidities are important causes of mortality.
Unfortunately, there is a paucity of data on the relation-
ship between PE and HIV co-infection both in developed
and developing countries [3–5].
Preeclampsia is heterogeneous in nature, and is associated
with differences in the timing of disease, clinical manifesta-
tions, severity of organ damage, maternal and foetal outcomes
and complications. The diverse nature of PE is further evident
in the severity in which it can manifest i.e. mild and severe
disease [6]. Although the definition of severe PE varies, it is
generally associated inter alia with markedly elevated blood
pressure, maternal neurological complications, seizures, signs
of hepatic and renal dysfunction, and foetal affectation [7]. In
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developing countries, severe forms of PE and eclampsia are
more common, and range from a low of 4% of all deliveries
to 18% in parts of Africa [8].
Preeclampsia is associated with a pro-inflammatory mi-
lieu, in which cytokines play a significant role as mediators
[9]. Whilst normal pregnancy also elicits an inflammatory
response, PE is characterised by an excessive inflammatory
response [10], and so it is important to look at the regula-
tion of the inflammatory cytokine mediators. A Th1/Th2
cell ratio imbalance has been hypothesised, skewing to-
wards the Th1 response [11], demonstrated by Toldi et al.
2011 [12]. Th1 cells are involved in pro-inflammatory
cytokine production and cell-mediated immunity; Th2
cells are involved in anti-inflammatory cytokine and
immune-suppressor cytokine production and B-cell
humoral immunity [10].
Other pathogenic mechanisms such as immune maladap-
tation, inadequate placental development and trophoblast
invasion, placental ischaemia, oxidative stress and throm-
bosis are all thought to represent key factors in the develop-
ment of PE [13]. All of these components have genetic
factors that may be involved in the pathogenesis [13], which
may alter susceptibility to preeclampsia or its complica-
tions. The genetic basis of PE is further supported by epi-
demiological findings that show a 2–5 fold increased risk of
PE in women with a maternal history of this disease [14].
MicroRNAs (miRNAs; miRs) are small (±22 nucleotides),
endogenous, non-coding RNA’s that regulate gene expres-
sion by modulating the expression of multiple target
mRNAs, inducing either translational inhibition or mRNA
degradation [15]. They are involved in various pathological
processes [15], including the regulation of innate and adap-
tive immune responses [16]. MiRNA-146a is involved in
modulating the negative regulation of Toll like receptor
(TLR) signalling, and inflammatory cytokines [17].
MiRNA-146a lies at the crossroads of biological processes
that involve innate-immune responses, viral-infection and
inflammatory disease [17]. It prevents an overstimulation of
the inflammatory response through its recognised target
genes, IRAK-1 and TRAF-6 [16, 18], and its dysregulation
is associated with many inflammatory diseases including
rheumatoid arthritis (RA) and systemic lupus erythemato-
sus (SLE) [15]. Its role in preeclampsia has not been
established.
Polymorphisms may affect miRNA expression, matur-
ation or mRNA recognition, and alter disease susceptibil-
ity [15]. A common miRNA-146a single nucleotide
polymorphism (SNP) (rs2910164) is located within the
seed sequence of pre-miRNA 146a, which is the miRNA-
146a precursor [19, 20]. This functional polymorphism
has been associated with various inflammatory diseases in-
cluding RA and SLE [21, 22].
Based on the inflammatory milieu in PE and HIV, the
regulatory role of miRNA-146a in inflammatory responses,
and the association of miRNA-146a rs 2910164 with in-
flammatory diseases, this study investigated the role of
rs2910164 in PE. Due to the high prevalence of HIV, we in-
cluded women with HIV infection on highly active anti-
retroviral therapy (HAART) in order to identify a possible
differential influence [4]. HAART is a standard treatment
consisting of a combination of at least three drugs. In the
present study, efavirenz, emtracitabine, and tenofovir were
used. To the best of our knowledge, this is the first investi-
gation in high risk Black SA women during pregnancy.
Methods
Study population and sample collection
Institutional ethical and hospital regulatory permission was
obtained for the study (Biomedical Research Ethics Com-
mittee, University of KwaZulu-Natal, South Africa; refer-
ence number BE119/11). After informed consent was
obtained, participants were recruited over a 14-month
period (from July 2013 to September 2014) at the maternity
unit at Prince Mshiyeni Memorial Hospital, Durban, South
Africa. This hospital is a regional level facility and serves a
predominantly semi-urban African population. Normoten-
sive [n = 95, (80 genotyped) age range: 16–46 years] and PE
patients [n = 98, (60 genotyped) age range: 16–42 years]
were enrolled into the study. To maintain ethnographic
and anthropometric consistency, all patients recruited were
of African descent, resident in the same geographical loca-
tion and of Zulu ethnicity. All patients were non-smokers,
non-consumers of alcohol or recreational drugs, and all
HIV infected patients were on HAART (tenofovir, emtrici-
tabine, efavirenz) as per the National guidelines [23]. Cal-
cium supplementation was administered routinely to all
patients attending the clinic. Women with gestational
hypertension, renal disease, diabetes mellitus, chronic
hypertension and collagen vascular disease were excluded
from this study. Preeclampsia was defined as a blood pres-
sure ≥140mmHg systolic or ≥ 90mmHg diastolic on two
occasions at least 4 h apart after 20 weeks of gesta-
tion in a woman with previously normal blood pressure
(<140mmHg systolic, >90mmHg diastolic), consistent with
guidelines [7]. All patients had proteinuria ≥1 on urine dip-
stick testing. Data on all patients was obtained from the in-
stitution’s maternity case records and laboratory data from
the National Health Laboratory Services® computerised
database at the institution. HIV was diagnosed on a rapid
test kit and weight was categorised as: normal weight (BMI:
18–25), overweight (BMI: 25–30), obese (BMI: 30+). Early
onset PE was considered as ≤34 weeks of gestation [24]. Se-
vere PE was diagnosed when features included any of the
following: systolic blood pressure ≥160mmHg or diastolic
blood pressure ≥110mmHg; maternal neurological disor-
ders such as persistent headaches and brisk reflexes,
eclampsia, acute pulmonary oedema, proteinuria ≥5g/day,
oliguria <500cc/day, creatinine >120μmol/L, features
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HELLP syndrome and thrombocytopenia <100,000/mm3,
foetal criteria including intrauterine growth retardation,
oligohydramnios, or foetal death in utero [6, 7].
Cytokine quantification
Since miR-146a is an inflammatory associated miRNA,
we decided to measure the levels of certain cytokines.
The BD Cytometric Bead Array Human Th1/Th2/Th17
Cytokine kit was used to measure Interleukin (IL)-2, IL-
4, IL-6, IL-10, IL17a and tumour necrosis factor-alpha
(TNF-α) protein levels in a serum samples. Briefly, ly-
ophilized standards were prepared by reconstitution and
serial dilution (1:2–1:256) in assay diluent immediately
before staining with Capture Beads and Phycoerythrin
Detection Reagent. All serum samples were also diluted
in assay diluent (1:4) before staining with Capture Beads
and Phycoerythrin Detection Reagent. For the staining
procedure, 50 μL of each standard and unknown sample
was added to appropriately labelled sample tubes
followed by 50 μL of the Human Th1/Th2/Th17 Phyco-
erythrin Detection Reagent and incubated (3 h, RT, pro-
tected from light). Following incubation 1 mL of Wash
Buffer was added to each assay tube and centrifuged at
200g for 5 min. The supernatant from each assay tube
was then carefully aspirated and 300 μL of Wash Buffer
was added to each assay tube to resuspend the bead pel-
let. Flow cytometric data was acquired using the BD
AccuriC6 Sampler counting 2100 gated events. This en-
sures that the sample file contains approximately 300
events per Capture Bead. Data analysis was performed
using the FCAP Array analysis software.
Genomic DNA extraction
Genomic DNA was extracted from whole blood samples
of the study subjects (80 normotensive and 60 PE). Cells
were transferred to 600μL lysis buffer (0.5% SDS,
150mM NaCl, 10mM EDTA, 10mM Tris-HCl (pH 8.0)).
To this, RNase A (100μg/mL; DNase free) was added to
the solution and incubated (37°C, 1h). Proteinase K
(200μg/mL) was then added and incubated (50 °C, 3h).
Protein contaminants were then precipitated by adding
5mM 0.1% potassium acetate before centrifugation
(5,000xg; 15min). Supernatants containing genomic
DNA were transferred to fresh tubes and extracted with
100% isopropanol on ice, and thereafter washed with
70% ethanol. DNA samples were dissolved in 10mM
Tris and 0.1mM EDTA (pH 7.4, 4 °C). DNA concentra-
tion was determined using the Nanodrop2000 spectro-
photometer, and all samples were standardised to a
concentration of 10ng/μL.
Genotyping
An optimised PCR was used to obtain the highest spe-
cificity and yield of the 147bp PCR product. This was
achieved by amplification of the genomic DNA using
40pmol of each primer (Forward Primer: 5’-
CATGGGTTGTGTCAGTGTCAGAGCT-3’; Reverse
Primer: 5’-TGCCTTCTGTCTCCAGTCTTCCAA-3’).
A no-template sample was run with the positive sam-
ples as a quality control measure against PCR contam-
ination. The 30μL reaction consisted of 200mM of each
dNTP, 2.5mM MgCl2, 1× Green GoTaq Flexi buffer,
0.2U Go-Taq DNA polymerase (Promega) and 30ng
genomic DNA template. PCR was performed under the
following cycling conditions: 94 °C for 10min (initial
denaturation), followed by 30 cycles of 94 °C for 30s,
65 °C for 30s (annealing) and 72 °C for 7min (final ex-
tension). PCR products were electrophoresed on agar-
ose gel (1.8%) and visualised using the Uvitech image
documentation system (Uvitech Alliance 2.7).
PCR–RFLP was used to determine the miR-146a
rs2910164 genotypes. Briefly, 15μL of each PCR prod-
uct was subjected to digestion by 1.5μL (10u/μL) Sac
I and 2μL 10x Buffer-Sac I (Fermentas). Overnight di-
gestion occurred at 37 °C, and thereafter digested
products were electrophoresed on agarose gel (3%)
and visualised as was the PCR product. Presence of
the wild-type G-allele resulted in no cleavage of the
PCR product. The variant C-allele yielded two frag-
ments of 122 and 25bp. The homozygous genotype
yielded three bands of 147, 122 and 25 bp. Restriction
products were run alongside a DNA ladder for accur-
ate reading of fragment sizes, thus enabling correct
analysis of genotypes (Fig. 1).
Statistical analysis
Statistical analysis was done using GraphPad Prism 5.0.
Correlation between continuous variables was assessed
using the Spearman rank correlation coefficient.
Fig. 1 Diagrammatic representation of PCR-RFLP product sizes and
corresponding genotypes. Lane 1 represents the PCR product
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Comparisons of mean across 3 or more groups were done
using the oneway ANOVA and Ad-hoc Kruskal–Wallis
test. The Pearson Chi-square (χ2) test was used to test as-
sociation between group(s) and categorical explanatory
variables. The Hardy–Weinberg equilibrium (HWE) was
used to test for deviation of allele/genotype frequency.
Allele and genotype frequencies were calculated using the
Fisher’s exact and Chi square tests, respectively. Severe PE
and early-onset PE were tested using the Barnard’s Test
using an online calculator (SciStatCalc, 2013: http://scistat
calc.blogspot.co.za/2013/11/barnards-test-calculator.html;
Author: Alijah Ahmed, Date Accessed: 01 December
2016). In the determination of significance, a p-value < 0.05
was deemed statistically significant.
Results
The clinical characteristics of participants are shown in
Table 1. The study cohort was divided into four subgroups
groups:
(1)HIV-uninfected preeclamptic women (PE HIV-)
(2)HIV-infected preeclamptic women (PE HIV+)
(3)HIV-uninfected normotensive women (Normo HIV-)
(4)HIV-infected normotensive women (Normo HIV+)
All women were in the third trimester of pregnancy and
the mean gestational age was 36.5 weeks of pregnancy.
There was a significant difference in the parity across all
groups (p = 0.006) but not between the HIV-positive
pre-eclamptic (PE) women and the normotensive
group (p = 0.400). There was also a significant differ-
ence in age across the groups (p = 0.002), and a sig-
nificant difference in both the systolic and diastolic
blood pressures between the total PE and normoten-
sive groups, between all four sub-groups, and between
PE HIV-positive women and normotensive HIV-positive
women (all p < 0.0001). Only IL-2, IL-17a, TNF-α and
IFN-γ showed significant differences between all four sub-
groups (respectively, p = 0.006; < 0.0001; 0.0008; 0.036),
and only IL-17a was significantly higher in the pre-
eclamptic group (p = 0.036) The average duration of
HAART was 16.6 and 14.5 weeks in the normotensive
and pre-eclamptic group respectively, however this is not
a precise duration of exposure. There were differences in
the mode of delivery; however these were based on obstet-
ric related indications. CD4 counts were not routinely per-
formed on uninfected women.
The genotype and allele frequencies are shown in Table 2.
There were no significant differences between the GC, CC
and GG genotypes (p = 0.430) or G/C allele frequen-
cies (p = 0.707) when compared between all preeclamptic
and all normotensive women. The genotype distribution
was compatible with the HWE in the study sample for
both the PE and normotensive groups (p = 0.627; p = 390).
Table 3 represents a sub-analysis of the genotype and
allele frequencies among women stratified according to
HIV status (i.e. negative or positive). No significant dif-
ferences were noted in the genotype or allele frequencies
by group comparison.
Table 4 represents the p values for the cytokines and
selected features associated with PE. There were no sig-
nificance differences noted with any of the mean cytokine
levels or the other variables assessed in the PE group and
sub-groups, except for severe preeclampsia, where the
variant (GC/CC) genotypes were associated with signifi-
cantly lower incidences of severe PE in both the total PE
group (p = 0.0497) and the PE HIV+ group (p = 0.017). In
the normotensive group, the variant genotypes were
associated with lower IL-2 in both the total normotensive
group (269 ± 1.26 (36) vs 273 ± 1.31 (23); p = 0.035) and
the PE HIV+ sub-group 265 ± 1.54 (19) vs 271 ± 1.38 (11);
p = 0.008).
Discussion
The dysregulation of miRNA146a has been associated
with inflammatory diseases such as RA and SLE [22, 25].
A downregulation of miRNA 146a has been found in
placentas of preeclamptic women compared with normal
women [26], therefore suggesting a potential role for
miRNA146a in the pathogenesis of preeclampsia. Based
on the presence of an increased inflammatory environ-
ment in preeclampsia [27–29], polymorphisms in the
miRNA146a gene may therefore affect susceptibility to
preeclampsia. The rs2910164 G > C polymorphism of
miRNA146a has recently been studied in inflammatory
conditions [25], however its role in preeclampsia and co-
morbid HIV infection has not been evaluated.
Inflammation is mediated by a variety of soluble fac-
tors, including cytokines [30], which were evaluated in
this study. Preeclampsia is characterised by significantly
higher levels of pro-inflammatory cytokines such as IL-6
and TNF-α, when compared with normal pregnant
women [31]. However, according to Celik et al. 2012,
studies on circulating interleukins are inconsistent [10].
This could be attributed to the fact that cytokines have a
short half-life and transient, episodic release [11], which
may even differ at different gestational periods, or the
fact that endothelial sensitivity to cytokines may differ
among women, rendering normal levels pathological
[11]. A speculation could be that SNPs could be involved
in cytokine dysregulation, resulting in the inconsistencies
noted. In HIV infection, the move away from a pro-
inflammatory cytokine milieu that occurs as disease pro-
gresses, is counteracted with the usage of HAART [32].
Our data did not show any significant association in the
frequency of the variant genotypes (GC/CC) in women
with preeclampsia and there was no significant association
in the groups stratified according to HIV. Furthermore,
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we did not find a significant relationship of the variant ge-
notypes with cytokines or the features of preeclampsia
that were assessed when stratified according to HIV status.
This could be due to the influence of the SNP on miR-
146a levels, and consequent expression of cytokines. How-
ever, it was found that IL-2, a pro-inflammatory cytokine
of the Th1 response, was significantly lower in the variant
genotypes for both the total normotensive group, and the
Table 3 Genotype and allele frequencies between groups
NORMO HIV-








GG 17 (40.5) 14 (36.8) 13 (41.9) 10 (34.5)
GC 20 (47.6) 18 (47.4) 12 (38.7) 12 (41.4)
CC 5 (11.9) 6 (15.8) 6 (19.4) 7 (24.1)
Allele n (%)
G 54 (64.3) 46 (60.5) 38 (61.3) 32 (55.2)
C 30 (35.7) 30 (39.5) 24 (38.7) 26 (44.8)

























Table 2 miR-146a genotype and allele frequency distribution in





p-value (Odds ratio; 95% CI)
Genotype n (%)
GG 31 (38.8) 23 (38.3) 0.430
GC 38 (47.5) 24 (40.0)
CC 11 (13.8) 13 (21.7)
Allele n (%)
G 100 (62.5) 70 (58.3) 0.707 (1.119; 0.6843–1.828)




Abbreviations: HWE Hardy Weinberg Equilibrium, CI confidence interval, G
guanine, C cytosine
Table 4 Clinical parameters analysed per genotype for pre-
eclampsia and normotensive groups
GC/CC vs. GGa
PE Total PE - PE +
Age 0.869 0.320 0.950
26.5 ± 1.11 (37) vs
26.8 ± 1.14 (36)
24.3 ± 1.28 (18) vs
26.0 ± 1.08 (26)
28.6 ± 1.68 (19) vs
28.8 ± 3.04 (10)
BMI 0.675 0.225 0.390
(31.7 ± 1.25 (29) vs
32.6 ± 1.92 (17))
(29.6 ± 1.66 (14) vs
34.4 ± 3.29 (8))
33.6 ± 1.77 (15) vs
31.1 ± 2.20 (9)
CD4 0.121 - 0.213
(414 ± 38.1 (20) vs
538 ± 65.0 (10))
408 ± 39.8 (19) vs
506 ± 63.4 (9)
SYS BP 0.866 0.875 0.671
160 ± 2.32 (45) vs
160 ± 3.91 (12)
158 ± 3.26 (23) vs
157 ± 8.69 (5)
161 ± 3.37 (22) vs
163 ± 3.04 (7)
DIA BP 0.817 0.654 0.412
104 ± 1.57 (45) vs
105 ± 3.16 (12)
102 ± 2.03 (23) vs
99.4 ± 6.04 (5)
105 ± 2.43 (22) vs








14 (38) vs 9 (39) 5 (28) vs 4 (31) 9 (47) vs 5 (50)
IL-2 0.201 0.240 0.885
262 ± 4.78 (10) vs
282 ± 13.1 (7)
268 ± 6.83 (4) vs
279 ± 5.09 (3)
258 ± 6.54 (6) vs
260 ± 7.54 (3)
IL-4 0.758 0.801 0.549
(247 ± 8.18 (10) vs
251 ± 5.29 (7))
261 ± 18.9 (4) vs
255 ± 7.34 (4)
238 ± 4.12 (6) vs
244 ± 7.08 (3)
IL-6 0.095 0.534 0.334
139 ± 7.93 (10) vs
171 ± 15.5 (7)
163 ± 14.5 (3) vs
181 ± 22.7 (4)
128 ± 6.66 (7) vs
158 ± 22.3 (3)
IL-10 0.895 0.697 0.107
147 ± 70.3 (9) vs
133 ± 70.4 (6)
273 ± 140 (4) vs
188 ± 147 (3)
45.4 ± 15.8 (5) vs
78.5 ± 2.77 (3)
IL-17a 0.758 0.475 0.511
1430 ± 313 (9) vs
1690 ± 728 (6)
820 ± 32.1 (4) vs
750 ± 79.3 (4)
1920 ± 466 (5) vs
3550 ± 1630 (2)
TNF-α 0.920 0.418 0.316
186 ± 15.4 (11) vs
183 ± 25.2 (7)
227 ± 25.4 (4) vs
179 ± 45.5 (4)
164 ± 14.0 (7) vs
189 ± 16.9 (3)
IFN-γ 0.315 0.507 0.668
206 ± 17.0 (11) vs
227 ± 11.2 (6)
201 ± 50.4 (4) vs
240 ± 10.6 (4)
208 ± 5.02 (7) vs
200 ± 12.6 (2)
Mean ± SEM (n)
Abbreviations: BMI body mass index (kg/m2), EOPE early onset preeclampsia,
SYS systolic, DIA diastolic, BP blood pressure (mmHg), IL interleukin, TNF-α
tumour necrosis factor alpha, IFN-γ interferon gamma
ap value
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stratified HIV+ group, indicating a possible role of the
SNP in reducing the pro-inflammatory response.
Another significant finding was that the incidence of se-
vere PE was significantly lower for the variant genotype in
the PE total and stratified PE HIV+ group, suggesting a re-
duced susceptibility for the development of severe disease
with the variant genotype, and a differential dysregulation
in the presence of HIV infection.
Severe PE is associated with adverse neonatal outcomes,
is more likely to recur [33], and is also associated with in-
creased maternal morbidity [34]. Moreover, women with
severe PE are at high risk for cardiovascular disease later
in life [35]. Eclamptic seizures, intracerebral haemorrhage,
pulmonary oedema or heart failure, acute renal failure,
liver dysfunction, and coagulation abnormalities are all as-
sociated with severe pre-eclampsia [36]. Foetal complica-
tions include intrauterine growth restriction, premature
delivery, and intrauterine foetal death [36]. Eclampsia, a
severe form of PE characterised by seizures, is associated
with a (0%-1.8%) mortality rate in developed countries
rising to a high rate of 15% in developing countries [37].
Furthermore, obesity is a known risk factor for PE [38], a
finding relevant to our study (mean BMI among the HIV
infected preeclamptic women was 32.5 kg/m2).
The role of miRNA-146a in HIV infection has emerged
more recently. Spinello et al. reported a relationship be-
tween miR146a and CXCR4 co-receptor in HIV [39].
Resting CD4 + T cells have high expression of miR-146a,
which inhibits the expression of the co-receptor CXCR4,
and prevents the HIV entry in CD4 +T cells [39, 40]. Fur-
thermore, Duskova et al. [41] demonstrated that miR-146a
was significantly increased in infected patients as com-
pared to healthy controls.
Our study demonstrates the relationship of miR-146a
rs2910164 G > C polymorphism with PE, some of the re-
lated features, cytokines and HIV/HAART. Of note is
the increased susceptibility to severe disease in local
women with the ancestral genotype, and reduced pro-
inflammatory circulating IL-2 levels in the normotensive
women with the variant genotypes.
Study Limitations
Our findings are preliminary and limited by a small sam-
ple size. Further, the influence of other functional poly-
morphisms on miR-146a expression in co-morbidities
needs further investigation, and the expression of miR-
146a needs to be measured. A larger cohort will enable
further research. This study was restricted to SA Black
women, thus our findings may not necessarily apply to
other ethnic groups.
Conclusion
MiR-146a rs2910164 G > C polymorphism might not be
associated with PE susceptibility, cytokines or related
features. However, the miR-146a GC/CC variant geno-
types might reduce susceptibility to severe PE, which
might be further influenced by the presence of co-
morbid HIV infection among pregnant women on
HAART.
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